| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERA.11.4 |
| P698 | PubMed publication ID | 21417858 |
| P2093 | author name string | H Miles Prince | |
| Rebecca A Howman | |||
| P2860 | cites work | Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes | Q24635226 |
| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy | Q24635408 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H | Q28215194 | ||
| Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study | Q28301671 | ||
| Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor | Q28972517 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma | Q33361638 | ||
| Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies | Q33364359 | ||
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies | Q33369463 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma | Q33376304 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project | Q33382121 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes | Q33387324 | ||
| Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma | Q33390353 | ||
| Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas | Q34147803 | ||
| Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma | Q34288599 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes | Q34594231 | ||
| Chromatin modification, leukaemia and implications for therapy. | Q34786248 | ||
| Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? | Q35189383 | ||
| Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan | Q35700236 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies | Q36129533 | ||
| Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy | Q36365590 | ||
| Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials | Q36591293 | ||
| Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity | Q36683412 | ||
| Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies | Q36836080 | ||
| Histone deacetylase inhibitors in lymphoma and solid malignancies | Q37118947 | ||
| Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma | Q37253554 | ||
| Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma | Q37321943 | ||
| Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. | Q37341209 | ||
| Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy | Q37411178 | ||
| Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. | Q37424784 | ||
| Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications | Q37512907 | ||
| Clinical studies of histone deacetylase inhibitors. | Q37512917 | ||
| Advances in the understanding and management of angioimmunoblastic T-cell lymphoma | Q37644544 | ||
| Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma | Q39336768 | ||
| Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas | Q39631042 | ||
| Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies | Q39700576 | ||
| The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis | Q39873607 | ||
| Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma | Q39883430 | ||
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 | ||
| Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab | Q40484548 | ||
| Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome | Q40566975 | ||
| Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports | Q40586132 | ||
| Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma | Q42942114 | ||
| Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group | Q42957470 | ||
| Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. | Q43249154 | ||
| Treatment of refractory T-cell malignancies using gemcitabine | Q43591855 | ||
| Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report | Q43775906 | ||
| Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas | Q43835095 | ||
| Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. | Q44195595 | ||
| Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics | Q44499666 | ||
| Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. | Q44509220 | ||
| A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas | Q44834795 | ||
| Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants | Q44848173 | ||
| Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. | Q44915322 | ||
| Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification | Q45059029 | ||
| A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. | Q45068216 | ||
| Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study | Q45069595 | ||
| Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide | Q45296407 | ||
| Epigenetic modifiers: basic understanding and clinical development. | Q45976173 | ||
| Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study | Q46124726 | ||
| Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience | Q46426412 | ||
| Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation | Q46459712 | ||
| Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group | Q46502896 | ||
| CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas | Q46820816 | ||
| Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma | Q46970940 | ||
| CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies | Q47697902 | ||
| A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. | Q47731944 | ||
| EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. | Q51764521 | ||
| Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. | Q53256121 | ||
| Angioimmunoblastic T-cell lymphoma. | Q53461776 | ||
| Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. | Q53551590 | ||
| Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. | Q54327371 | ||
| In situ depletion of CD4+ T cells in human skin by Zanolimumab | Q56908903 | ||
| P433 | issue | 3 | |
| P921 | main subject | pralatrexate | Q637059 |
| P304 | page(s) | 457-472 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Expert Review of Anticancer Therapy | Q2999044 |
| P1476 | title | New drug therapies in peripheral T-cell lymphoma | |
| P478 | volume | 11 |
| Q54456214 | Advances in the management of skin cancer. |
| Q48665990 | An audit of patients with mature T-cell non-Hodgkin lymphoma by transplant status in Tasmania |
| Q35964716 | Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer |
| Q37061792 | Epigenetics and colorectal cancer pathogenesis |
| Q34575453 | Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients |
| Q35592607 | Histone deacetylase inhibitors: emerging mechanisms of resistance. |
| Q33403802 | Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. |
| Q43696519 | Peripheral T-cell lymphomas: in "real life" experience are we really improving? |
| Q37226511 | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| Q35821728 | Targeting Histone Deacetylases in Diseases: Where Are We? |
| Q48301800 | The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. |
Search more.